Procaps Group SA
NASDAQ:PROC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.68
4.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PROC stock under the Base Case scenario is 4.3594 USD. Compared to the current market price of 2.1612 USD, Procaps Group SA is Undervalued by 50%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Procaps Group SA
Run backtest to discover the historical profit from buying and selling PROC based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Procaps Group SA
Balance Sheet Decomposition
Procaps Group SA
Current Assets | 298.4m |
Cash & Short-Term Investments | 25.8m |
Receivables | 170.9m |
Other Current Assets | 101.7m |
Non-Current Assets | 200.2m |
Long-Term Investments | 6.2m |
PP&E | 137.4m |
Intangibles | 47.1m |
Other Non-Current Assets | 9.6m |
Current Liabilities | 202.9m |
Accounts Payable | 89.8m |
Other Current Liabilities | 113.2m |
Non-Current Liabilities | 256.2m |
Long-Term Debt | 220.7m |
Other Non-Current Liabilities | 35.6m |
Earnings Waterfall
Procaps Group SA
Revenue
|
414.2m
USD
|
Cost of Revenue
|
-186.2m
USD
|
Gross Profit
|
228m
USD
|
Operating Expenses
|
-194.2m
USD
|
Operating Income
|
33.8m
USD
|
Other Expenses
|
18.4m
USD
|
Net Income
|
52.2m
USD
|
Free Cash Flow Analysis
Procaps Group SA
USD | |
Free Cash Flow | USD |
Despite a challenging first half of 2023, Procaps Group is charting a path to recovery. Hindered by macroeconomic conditions such as high inflation and interest rates, Procaps faced reduced orders and rising costs. However, these are considered temporary, and the company's recovery is evident through a 4.3% revenue increase for Q2 and 7% for the first half of the year compared to the same period in the previous year. Their prescription and clinical specialties segments grew by 15% and 6% respectively, outperforming the market. New products also contributed significantly, earning $66 million and comprising 34% of total revenues. Looking ahead, aggressive cost-cutting and efficiency measures, alongside a robust product pipeline, are expected to bolster growth. Gross profit has declined due to these headwinds, yet the company is poised for a stronger Q4, indicating optimism in its long-term strategy and efforts to achieve carbon neutrality.
What is Earnings Call?
PROC Profitability Score
Profitability Due Diligence
Procaps Group SA's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Procaps Group SA's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
PROC Solvency Score
Solvency Due Diligence
Procaps Group SA's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Score
Procaps Group SA's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PROC Price Targets Summary
Procaps Group SA
According to Wall Street analysts, the average 1-year price target for PROC is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
Dividends
Current shareholder yield for PROC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
Officers
The intrinsic value of one PROC stock under the Base Case scenario is 4.3594 USD.
Compared to the current market price of 2.1612 USD, Procaps Group SA is Undervalued by 50%.